73 related articles for article (PubMed ID: 6574820)
21. Phase II trial of ICRF-187 in non-small cell lung cancer.
Natale RB; Wheeler RH; Liepman MK; Sauder A; Bricker L
Cancer Treat Rep; 1983 Mar; 67(3):311-3. PubMed ID: 6403240
[No Abstract] [Full Text] [Related]
22. Phase II trial of epirubicin in hepatoma.
Shiu W; Mok SD; O SK; Tsao SY; Woo KS; Li A; Leung N; Martin C
Cancer Treat Rep; 1986 Aug; 70(8):1035-6. PubMed ID: 3015405
[No Abstract] [Full Text] [Related]
23. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma.
Ajani JA; Kanojia MD; Bodey GP
Cancer Treat Rep; 1984 Dec; 68(12):1507-8. PubMed ID: 6595058
[No Abstract] [Full Text] [Related]
24. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
[No Abstract] [Full Text] [Related]
25. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
Nishio M; Ohata M; Kobayashi H; Suruda T; Uetani K; Funasako M; Nishio K; Sasaki Y; Saijo N
Jpn J Clin Oncol; 1993 Oct; 23(5):284-90. PubMed ID: 8230753
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma.
Coates AS; Fox RM; Woods RL; Levi JA; Tattersall MH
Cancer Treat Rep; 1982 Jan; 66(1):177-8. PubMed ID: 7053255
[TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.
Sculier JP; Bureau G; Giner V; Thiriaux J; Michel J; Berchier MC; Van Cutsem O; Küstner U; Kroll F; Mommen P
Semin Oncol; 1995 Feb; 22(1 Suppl 2):18-22. PubMed ID: 7846537
[TBL] [Abstract][Full Text] [Related]
28. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II).
Mills RC; Maurer LH; Forcier RJ; Grace WR; Burke GP; Karp DD; Smith RC; Mcintyre OR; Bean C
Cancer Treat Rep; 1977; 61(3):477-9. PubMed ID: 872146
[No Abstract] [Full Text] [Related]
30. A phase of I trial of 4'-epi-Adriamycin.
Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW
Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
32. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
33. [Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group].
Yoneda S; Nishiwaki Y; Niitani H; Kurita Y; Ariyoshi Y; Ikegami H; Furuse K; Fukuoka M; Kimura I; Hara N; Saijo N
Gan To Kagaku Ryoho; 1996 May; 23(6):695-701. PubMed ID: 8645020
[TBL] [Abstract][Full Text] [Related]
34. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
35. [Action of adriamycin on primary and metastatic pulmonary neoplasms and on neoplastic pleural effusions].
Mariani B; Saltini C; Velluti G; Bisetti A; Marchioni CF; Monzali G
Atti Accad Med Lomb; 1975; 30(1-3):169-207. PubMed ID: 1234847
[No Abstract] [Full Text] [Related]
36. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
37. [Clinical trial of epirubicin in patients with cardiologic contraindications for the use of doxorubicin].
Pawlicki M; Zuchowska-Vogelgesang B; Maciejewicz J
Przegl Lek; 1987; 44(4):414-7. PubMed ID: 3306806
[No Abstract] [Full Text] [Related]
38. An attempt at applying epiadriamycin to the patients for whom doxorubicin is cardiologically contraindicated.
Pawlicki M; Zuchowska-Vogelgesang B; Maciejewicz J; Kojder R
Neoplasma; 1986; 33(5):649-55. PubMed ID: 3466045
[TBL] [Abstract][Full Text] [Related]
39. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer].
Haneda H; Koizumi M; Hayashi T
Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
